BBC Ordered to Pay Damages for < > Fake News About Trump

New Post Public Reply Private Reply Replies (0) Message Board
PoemStone
213
BBC Ordered to Pay Damages for < >
Fake News About Trump and Ukraine President

A-BBC-logo-is-pictured-on-a-television-screen-inside-New-Broadcasting-House-in-central-London-Getty-640x480.png

The BBC was ordered to pay damages after the far-left outlet published fake news claiming Ukraine President Petro Poroshenko “authorized” an illegal payment of $400,000 to Michael Cohen for additional face time during a June 2017 meeting with President Trump.

“We apologize to Mr. Poroshenko for any distress caused and have agreed to pay him damages, legal costs and have participated in a joint statement in open court,” the BBC’s said in a written apology published Thursday.

In the May 2018 piece, the disgraced BBC made the absurd claim that Poroshenko, who already had a meeting set up with Trump, paid this $400,000 to extend the meeting.
Breitbart TV
If James Carville Is Right, Trump Has Massive Lead Over Any Dem. Opponent

Think about how well this utterly deranged piece of fake news fits into the overall media’s Russia Collusion Hoax.

Poroshenko is an aggressive opponent of Russian President Vladimir Putin, so naturally the only way he could get serious face time with Trump (aka Putin’s Stooge) is through a six-figure bribe.
Michael Cohen was still the president’s personal lawyer at this time, which means the media were desperate for us to see Cohen as Trump’s world-traveling bagman, because that would lend credibility to the phony dossier’s lie about Cohen visiting Prague to pay off the hackers who got Hillary’s emails.
The story openly insinuates Trump is both in Putin’s pocket and accepting bribes.

In a way you have to admire the slickness of it — the triple bank-shot of hysteria the BBC hoped to sink.

But it is also preposterous. Who in their right mind would believe a billionaire like Trump would risk his presidency (and prison) for a lousy $400,000, or use Cohen to arrange it?

Just as preposterous, though, is the whole idea Trump was a traitor who stole a presidential election, and we were hit with that media-lunacy 24/7 for two years.

More from the BBC:

In our News at Ten bulletin and in an online article published on May 23, 2018, we incorrectly reported that Petro Poroshenko, the President of Ukraine, had procured or authorised a corrupt payment of $400,000 to be made to Michael Cohen, the personal lawyer of Donald Trump, to extend a brief meeting between Mr. Poroshenko and President Trump, that had already been agreed, into more substantial talks.

No word yet on the amount of damages paid by the BBC, but it is good to see some justice done. The idea a news outlet can smear anyone they like, hide behind freedom of the press, and suffer no consequence is outrageous.

Let’s hope Nick Sandmann is delivered a similar form of justice very, very soon.

Poroshenko, who is running for re-election, sued the BBC over the report. Election Day is March 31.
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 35

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 26

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 23

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 32

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Kotak Mahindra Bank's Innovative Tech Strategies

Updated Category News Views 587

Kotak Mahindra Bank's Commitment to Digital Transformation Kotak Mahindra Bank is at the forefront of revolutionizing financial services through its innovative technology strategies. Their latest report dives deep into the bank's extensive tech activities, highlighting how it leverages digital transformation to enhance customer experience and streamline operations....

Continue Reading
Star Group, L.P. Reflects on Fiscal 2024 Performance Updates

Updated Category News Views 349

Star Group's Fiscal 2024 Insights and Performance Analysis As the fiscal year wraps up, Star Group, L.P. (NYSE: SGU), a respected home energy distributor, shares its financial performance that ended on September 30, 2024. Amidst the prevailing challenges in the energy market, the company continues its commitment to delivering quality services while adapting to market...

Continue Reading
Krystal Biotech Launches Clinical Trial for Eye Therapy KB801

Updated Category News Views 148

Krystal Biotech Begins Phase 1/2 Trial of KB801 Krystal Biotech, Inc. (NASDAQ: KRYS) has recently announced exciting developments in its ophthalmology pipeline with the initiation of a Phase 1/2 clinical trial for KB801, aimed at treating neurotrophic keratitis (NK). This 2:1 randomized, double-masked, multicenter, placebo-controlled study, named EMERALD-1, marks a...

Continue Reading
Key Updates on the Annual General Meeting of Ignitis Group

Updated Category News Views 163

Exciting Updates for the Ignitis Group Shareholders The retained earnings figure for AB “Ignitis grup?” has been amended for the upcoming Annual General Meeting. It now stands at EUR 320,319,368.41, following a revision made only to the English version of the document. This adjustment reflects the company’s commitment to transparency and accuracy in their financial...

Continue Reading
Transforming Connectivity: The Future of mmWave Sensors Growth

Updated Category News Views 104

The mmWave sensors market was set on a blistering growth path back in 2023, valued at around USD 0.25 billion. By the time you fast-forward to 2032, projections had it skyrocketing to USD 2.40 billion, boasting a staggering CAGR of 28.59% from 2024 through 2032. You'd think this kind of momentum would have traders buzzing—oh wait, they were, especially as the push for...

Continue Reading